Inhaled Furosemide for Transient Tachypnea of Newborn

Makassed General Hospital64 enrolled

Overview

This is a randomized double blind clinical trial in which newborns with suspected Transient tachypnea of the newborn (TTN) will receive either furosemide or normal saline by nebulizer every 6 hours for 24 hours.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

TRIPLE

Enrollment

Conditions

Respiratory Morbidity

Interventions

FurosemideOTHER

Patients will receive nebulised furosemide solution 1 mg/kg

PlaceboOTHER

Patients will receive nebulised 0.9% saline

Eligibility

Sex: ALLMin age: 1 DayMax age: 1 Day

Medical Language ↔ Plain English

Inclusion Criteria: * Neonates with 34+0-39+0 gestational age * on the first day of life * with the clinical diagnosis of Transient Tachypnoea * need for CPAP \>6 hours to obtain the oxygen saturation \>92% Exclusion Criteria: * Systemic infection * Intubation and mechanical ventilation before Inclusion in the trail * Malformation and any other disease with disturb of respiratory system

Locations (1)

Makassed General Hospital

Beirut, Lebanon

Outcomes

Primary Outcomes

Percentage of patients with respiratory morbidity

Neonatal respiratory morbidity will be assessed through oxygen saturation, respiratory rate and duration on Continuous positive airway pressure (CPAP)

Time frame: 24 hours

Secondary Outcomes

Length of hospital stay

Duration of hospital stay in days

Time frame: 15 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.